Nivolumab plus relatlimab vs nivolumab alone for the adjuvant treatment of completely resected stage III-IV melanoma: Primary results from RELATIVITY-098 Meeting Abstract
| Authors: | Long, G. V.; Ascierto, P. A.; Guo, J.; Chandra, S.; Tarhini, A. A.; Couselo, E. M.; Del Vecchio, M.; De Melo, A. C.; Gogas, H.; Dummer, R.; Callahan, M. K.; Schadendorf, D.; Koelblinger, P.; Quereux, G.; Thomas, I.; Chen, B.; Cheong, A. M. Y.; Djidel, P.; Dolfi, S.; Tawbi, H. A. |
| Abstract Title: | Nivolumab plus relatlimab vs nivolumab alone for the adjuvant treatment of completely resected stage III-IV melanoma: Primary results from RELATIVITY-098 |
| Meeting Title: | 2025 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 17 Suppl. |
| Meeting Dates: | 2025 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-06-10 |
| Start Page: | LBA9500 |
| Language: | English |
| ACCESSION: | WOS:001511770600001 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2025.43.17_suppl.LBA9500 |
| Notes: | Meeting Abstract -- Source: Wos |
